OPK-88004

OPK-88004 (formerly known as LY-2452473 or TT-701) is a non-steroidal indole derivative which acts as a selective androgen receptor modulator (SARM). It has been investigated by OPKO Health for the treatment of erectile dysfunction and symptoms associated with benign prostate hyperplasia.^[1][2][3]

OPK-88004

Legal status
Legal status	US: Investigational new drug
Identifiers
IUPAC name propan-2-yl N-[(2S)-7-cyano-4-(pyridin-2-ylmethyl)-2,3-dihydro-1H-cyclopenta[b]indol-2-yl]carbamate
CAS Number	1029692-15-6 Y
PubChem CID	24963749
UNII	XKW9MYF94Y
CompTox Dashboard (EPA)	DTXSID50145591
Chemical and physical data
Formula	C22H22N4O2
Molar mass	374.444 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)OC(=O)N[C@H]1CC2=C(C1)N(C3=C2C=C(C=C3)C#N)CC4=CC=CC=N4
InChI InChI=1S/C22H22N4O2/c1-14(2)28-22(27)25-17-10-19-18-9-15(12-23)6-7-20(18)26(21(19)11-17)13-16-5-3-4-8-24-16/h3-9,14,17H,10-11,13H2,1-2H3,(H,25,27)/t17-/m0/s1 Key:IHIWYQYVBNODSV-KRWDZBQOSA-N

Research

The compound advanced to a phase II trial in benign prostatic hyperplasia, but it was terminated due to difficulty in measuring prostate size, the trial's primary endpoint.^[4]

It was also tried in a study to improve quality of life in patients with prostate cancer. Although it did not cause progression of the disease and increased lean body mass, the drug did not improve sexual function.^[3]

See also

• Enobosarm
• JNJ-28330835
• Ligandrol